Research programme: hepatitis C virus NS3 protein inhibitors - IRBMAlternative Names: Hepatitis C virus NS3 protease inhibitors research programme - IRBM
Latest Information Update: 22 Apr 2003
At a glance
- Originator IRBM
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 08 Sep 2000 Preclinical development for Hepatitis C in Italy (Unknown route)